Departments of Pathology and Oncology, Sol Goldman Pancreatic Cancer Research Center, Johns Hopkins University School of Medicine, Baltimore, Maryland.
Division of Gastroenterology and Hepatology, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland.
Gastroenterology. 2022 Aug;163(2):386-402.e1. doi: 10.1053/j.gastro.2022.03.056. Epub 2022 Apr 7.
Pancreatic ductal adenocarcinoma (PDAC) is a clinically challenging cancer, due to both its late stage at diagnosis and its resistance to chemotherapy. However, recent advances in our understanding of the biology of PDAC have revealed new opportunities for early detection and targeted therapy of PDAC. In this review, we discuss the pathogenesis of PDAC, including molecular alterations in tumor cells, cellular alterations in the tumor microenvironment, and population-level risk factors. We review the current status of surveillance and early detection of PDAC, including populations at high risk and screening approaches. We outline the diagnostic approach to PDAC and highlight key treatment considerations, including how therapeutic approaches change with disease stage and targetable subtypes of PDAC. Recent years have seen significant improvements in our approaches to detect and treat PDAC, but large-scale, coordinated efforts will be needed to maximize the clinical impact for patients and improve overall survival.
胰腺导管腺癌(PDAC)是一种临床挑战性癌症,这是由于其在诊断时已经处于晚期,并且对化疗具有抗性。然而,我们对 PDAC 生物学的理解的最新进展揭示了用于 PDAC 的早期检测和靶向治疗的新机会。在这篇综述中,我们讨论了 PDAC 的发病机制,包括肿瘤细胞中的分子改变、肿瘤微环境中的细胞改变以及人群水平的风险因素。我们回顾了 PDAC 的监测和早期检测的现状,包括高危人群和筛查方法。我们概述了 PDAC 的诊断方法,并强调了关键的治疗考虑因素,包括治疗方法如何随疾病阶段和 PDAC 的可靶向亚型而变化。近年来,我们在检测和治疗 PDAC 方面取得了重大进展,但需要大规模、协调一致的努力,才能使患者获得最大的临床获益并提高总体生存率。